Concourse Financial Group Securities, Inc. Lantern Pharma Inc. Transaction History

Concourse Financial Group Securities, Inc.

$0
Q2 2025

Number of Shares

Previous 0 NaN%

Holding current value

Previous $0 NaN%

% of portfolio

100.0%

Previous 100.0%

22 transactions

Quarter	Operation	Price Per share
Q2 2025 Aug 12, 2025	BUY	$2.58 - $4.34 $0 - $0
Q1 2025 May 14, 2025	BUY	$3.3 - $5.42 $0 - $0
Q4 2024 Feb 13, 2025	BUY	$2.9 - $4.26 $0 - $0
Q3 2024 Oct 10, 2024	BUY	$3.42 - $4.83 $0 - $0
Q2 2024 Jul 23, 2024	BUY	$3.91 - $9.51 $0 - $0
Q1 2024 Apr 30, 2024	BUY	$3.73 - $10.65 $0 - $0
Q4 2023 Feb 07, 2024	BUY	$2.48 - $4.39 $0 - $0
Q3 2023 Oct 30, 2023	BUY	$3.41 - $5.51 $0 - $0
Q3 2023 Oct 25, 2023	BUY	$3.41 - $5.51 $0 - $0
Q2 2023 Aug 10, 2023	BUY	$4.56 - $6.02 $0 - $0
Q1 2023 May 15, 2023	BUY	$4.3 - $6.2 $0 - $0
Q4 2022 Jan 30, 2023	BUY	$4.19 - $6.04 $0 - $0
Q3 2022 Nov 15, 2022	BUY	$4.59 - $6.5 $0 - $0
Q2 2022 Aug 09, 2022	BUY	$4.82 - $7.45 $0 - $0
Q1 2022 May 09, 2022	BUY	$5.6 - $8.22 $0 - $0
Q4 2021 Feb 07, 2022	BUY	$7.11 - $11.04 $0 - $0
Q3 2021 Nov 09, 2021	BUY	$10.53 - $14.93 $0 - $0
Q2 2021 Aug 13, 2021	BUY	$12.94 - $19.89 $0 - $0
Q1 2021 May 13, 2021	BUY	$14.34 - $21.92 $0 - $0
Q4 2020 Feb 02, 2021	BUY	$15.1 - $20.69 $0 - $0
Q3 2020 Nov 13, 2020	BUY	$10.7 - $21.25 $0 - $0
Q2 2020 Aug 13, 2020	BUY	$11.54 - $14.95 $0 - $0

Others Institutions Holding LTRN

# of Institutions

Shares Held

2.19M

Call Options Held

16.4K

Put Options Held

Bios Capital Management, LP Fort Worth, TX

1.02M
Shares

$3.6 Million
4.97% of portfolio
Vanguard Group Inc Valley Forge, PA

384K
Shares

$1.36 Million
0.0% of portfolio
Cm Management, LLC

200K
Shares

$708,000
0.65% of portfolio
Geode Capital Management, LLC Boston, MA

92.1K
Shares

$325,966
0.0% of portfolio
Jim Simons Renaissance Technologies LLC | New York, Ny

90.6K
Shares

$320,724
0.0% of portfolio

View Full List

About Lantern Pharma Inc.

Ticker LTRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,830,900
Market Cap $38.3M
Description
Lantern Pharma Inc., a clinical stage biotechnology company, focuses on artificial intelligence, machine learning, and genomic data to streamline the drug development process. Its advanced drug candidate is LP-100, which is in phase II clinical trials to treat metastatic, castration-resistant, and prostate cancer. The company also develops LP-30...

More about LTRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Concourse Financial Group Securities, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Concourse Financial Group Securities, Inc. with notifications on news.

Account